Announcements
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
The prognostic and predictive value of ERCC-1, p53, bcl-2 and bax in epithelial ovarian cancer
K. Avraam1, K. Pavlakis1,*, C. Papadimitriou2, T. Vrekoussis3, T. Panoskaltsis4, I. Messini5, E. Patsouris1
Show Less
1
First Department of Pathology
2
Department of Clinical Therapeutics of Alexandra Hospital, Medical School, University of Athens
3
Department of Pathology, Medical School, University of Crete
4
Gynaecological Oncology Unit, Iaso Women’s Hospital
5
Department of Pathology, Iaso Women’s Hospital, Athens (Greece)
Eur. J. Gynaecol. Oncol. 2011, 32(5), 516–520;
Published: 10 October 2011
Abstract
Aim: To evaluate the expression of ERCC-1 in patients with epithelial ovarian cancer (EOC) and to correlate it with the expression of p53, bcl-2 and bax. Materials and Methods: Tumor samples from 60 patients with EOC were immunohistochemically investigated for the expression of ERCC1, p53, bcl-2 and bax. Results: ERCC-1 expression was significantly decreased in serous and endometrioid compared to clear cell carcinomas. P53 expression was significantly increased in serous compared to clear cell carcinomas. Bax expression was significantly increased in serous carcinomas as compared to MMTs. High disease stage was correlated with low ERCC-1 and high bcl-2 expression. ERCC-1 expression was associated with increased disease-free interval. Conclusion: ERCC-1 status seems to be correlated with disease-free interval, stage and tumor histologic subtype in patients with EOC. Nevertheless, our results indicate that single-gene expressions may be unreliable and thus caution is needed when used as potential prognostic or predictive markers.
Keywords
Ovarian cancer
ERCC-1
p53
bcl-2
bax